<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802449</url>
  </required_header>
  <id_info>
    <org_study_id>11-08-2333</org_study_id>
    <secondary_id>7U54MD008149</secondary_id>
    <nct_id>NCT02802449</nct_id>
  </id_info>
  <brief_title>To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans</brief_title>
  <official_title>An Eight Week Double Blinded Randomized, Placebo-controlled Trial to Assess the Effect of Two Doses of 100,000 IU Vitamin D3 by Mouth on Select Genetic Responses in Overweight, Hypertensive African-Americans With Hypovitaminosis D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Morehouse School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three hundred thirty (330) overweight, pre-hypertensive/controlled hypertensive,
      African-American participants will be enrolled in a 8 week study to assess the effect of two
      administrations of Vitamin D3 on Vitamin D serum responsiveness as a function of clinical,
      biologic and genetic factors. The investigators anticipate that at least 300 participants
      will complete this study.

      Written, signed and dated informed consent to participate in the study will be given by the
      participant or a legally acceptable representative, in accordance with the International
      Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable
      regulations, before completing any study-related activities/procedures. The original signed
      and dated consent will be kept in the subject's research file and a copy given to the
      subject. A copy will also be placed in their medical record.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DETAILED DESCRIPTION OF STUDY PROCEDURES. Three hundred thirty (330) overweight,
      pre-hypertensive/controlled hypertensive, African-American participants will be enrolled in a
      8 week study to assess the effect of two administrations of Vitamin D3 on Vitamin D serum
      responsiveness as a function of clinical, biologic and genetic factors. The investigators
      anticipate that at least 300 participants will complete this study.

      Written, signed and dated informed consent to participate in the study will be given by the
      participant or a legally acceptable representative, in accordance with the International
      Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable
      regulations, before completing any study-related activities/procedures. The original signed
      and dated consent will be kept in the subject's research file and a copy given to the
      subject. A copy will also be placed in their medical record.

      BLOOD PRESSURE CONTROL. Controlled high blood pressure is entry criteria, but not an outcome.
      However, the investigators want to exclude potential participants who are likely to have poor
      BP control during the study. Therefore, although patients with pre-hypertension or
      hypertension are eligible to be entered into the study, the protocol only allows enrollment
      of participants with well-controlled hypertension as defined by SBP≥ 120 mmHg or DBP ≥ 80
      mmHg if not on treatment, and SBP &lt;160 mmHg or DBP &lt; 100 mmHg regardless of whether on
      treatment or not. BP care will be managed by the participants' primary or other provider. All
      participants being actively treated for hypertension with pharmacotherapy will receive
      direction to adhere to their medication and to follow-up with their Primary Care Physician.
      Patients with poorly controlled diabetes as defined by hemoglobin A1c &gt; 8.5% or advanced
      kidney disease as defined by eGFR &lt; 45 ml/min are excluded. After the study is concluded, all
      participants will be encouraged and supported to address issues of diet and exercise that may
      reduce their risk for hypertension. If BP medications need to be adjusted, participants will
      be referred back to their Primary Care Physician.

      VISIT 1 - SCREENING. The screening period will allow for the determination of appropriateness
      of each subject's inclusion in the study. Written informed consent from the subject or their
      legally authorized representative would have been obtained prior to any study-related
      procedures being performed. In addition to signing the general informed consent, subjects who
      agree to participate the sub-study with fat biopsy will sign a second informed consent.

      The subject will be assigned a screening number and will be contacted regarding eligibility
      once all screening procedures have been performed and laboratory results received.

      The following evaluations and assessments will be performed during Screening:

      inclusion/exclusion criteria, medical history (including demographics and concomitant
      medications, including prescription, herbal/vitamins, and all over-the-counter medications),
      vital signs (sitting BP, heart rate), and a mini physical examination (which will include
      height (cm), weight (kg), and waist circumference (cm) from which body mass index (BMI) will
      be calculated and a clinical heart/lung examination. Blood will be drawn (15 cc) for full
      biochemistry panel with glucose (mg/dl), complete blood count, HbA1c (%), calcium (mg/dl),
      phosphorus (mg/dl), albumin (mg/dl), pregnancy test and 25(OH)D (ng/ml) levels. After
      screening information is reviewed and deemed to be appropriate for inclusion in the study,
      eligible subjects will be given an appointment and preparatory instructions for Visit 2
      (Baseline/Randomization/Dose#1). Instructions include cessation of smoking (if they smoke),
      eating, or drinking caffeine for at least 8 hours prior to the Baseline Visit. If
      participants are taking prescribed medications, they will be asked to bring them and advised
      to take them as prescribed.

      VISIT 2 - BASELINE/ RANDOMIZATION/ STUDY DRUG DOSE#1 ADMINISTRATION. If subject meets all of
      the inclusion/exclusion criteria, they will be randomized. The participant will be asked
      about any adverse events and changes in medications, including prescription, herbal/vitamin,
      and over-the-counter medications. Vital signs (sitting BP, heart rate) will be obtained and a
      nutritional survey administered. Blood will be drawn (45 cc) for serum calcium (mg/dl),
      phosphorus (mg/dl), albumin (mg/dl), iPTH (pg/ml) and 1-84 PTH/7-84 PTH ratio, pregnancy
      test, 25(OH)D (ng/ml) levels; and samples stored for bio-markers (e.g.
      pro-inflammatory/pro-thrombotic/fibrotic, insulin sensitivity, and vitamin D receptor
      polymorphisms). Spot urine sample (30cc) will be collected for calcium/creatinine and
      albumin/creatinine ratios as well as sodium and isoprostanes. The fat biopsy will be
      performed on those that agree to be part of the subgroup. Participants undergoing the fat
      biopsy will be given post biopsy instructions including a return appointment in 7-10 days.

      Visit will last about 30-60 minutes for most participants. At the end of the visit,
      participant will be randomized and given either two 50,000 IU tablets of oral Vitamin D3
      [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] or two tablets of
      Placebo (microcrystalline cellulose) to take under direct observation. All the participants
      will be given an appointment and preparatory instructions for Study Visit 3. They will also
      be asked to avoid any other vitamin D supplements during study period.

      VISIT 3 - STUDY DRUG DOSE#2 ADMINISTRATION (2 weeks after baseline). Visit will last about 15
      minutes for most participants. Participant will be asked about any adverse events and changes
      in medications, including prescription, herbal, and over-the-counter medications. Vital signs
      will be obtained. Participant will be given their second dose of either two 50,000 IU tablets
      of oral Vitamin D3 or two tablets of Placebo to take under direct observation. All the
      participants will be given an appointment and preparatory instructions for Study Visit 4
      (Week 6).

      VISIT 4 (Week 6). During this visit participant will be asked about any adverse events
      including possible symptoms of vitamin D overdose and changes in medications, including
      prescription, herbal, and over-the-counter medications. In addition, the following
      evaluations and assessments will also be performed: vital signs (sitting BP, heart rate).
      Blood will be drawn (3 tablespoon or 45 cc) for full biochemistry panel, with glucose
      (mg/dl), HbA1c (%), complete blood count, calcium (mg/dl), phosphorus (mg/dl), albumin
      (mg/dl), iPTH (pg/ml) and 1-84 PTH/7-84 PTH ratio, and 25(OH)D (ng/ml) levels; and stored
      samples for bio markers (e.g. pro-inflammatory/pro- thrombotic/fibrotic, insulin sensitivity,
      and vitamin D receptor polymorphisms). Spot urine sample will be collected for
      calcium/creatinine and albumin/creatinine ratios as well as sodium and isoprostanes. Urine
      pregnancy test will also be done. Participants undergoing the fat biopsy will be given post
      biopsy instructions and will have an additional 7-10 days of follow-up.

      VISIT 5 - END OF STUDY (Week 8). At the End of Study visit (EOS), participant will be asked
      about any adverse events including possible symptoms of vitamin D overdose. In addition, the
      following evaluations and assessments will also be performed: vital signs (sitting BP and
      heart rate). The results of the labs from the previous visit will be discussed and if there
      are any abnormal lab values, participant will be referred to primary care physician for
      further management.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma PTH Level</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Building upon our hypothesis above, this aim exploits the fact that the nuclear Vit-D Receptor (VDR) regulates parathyroid hormone (PTH) gene transcription. Therefore the plasma PTH level serves as a sensitive biomarker of the Vit-D nutri-genomic response. This aim will define the multivariate determinants (covariates such as age, BMI, baseline Vit-D level and dietary calcium) of the Vit-D-PTH level relationship (the primary outcome variable) in African-Americans. It is anticipated that the Vit-D supplementation trial will document a wide variance of Vit-D-PTH level relationships that will identify patients at the upper and lower quartiles of the distribution that are either 'nutrient-responsive' or 'nutrient-resistant'. These studies should help identify the 'clinical' characteristics of the sub-set of African-Americans that exhibit the poorest response to Vit-D supplementation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D3 Level</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: Cysteine</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: Homocysteine</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: GSH</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: Isoprostane</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 hydroxy-Vitamin D3 or [25 (OH) D3]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 Hydroxy- Vitamin D3 [25 (OH) D3]</intervention_name>
    <description>Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
    <arm_group_label>25 hydroxy-Vitamin D3 or [25 (OH) D3]</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, 18-70 years of age and self-identified as African-American or Black

          -  Pre-hypertension or hypertension (well controlled - see below)

          -  If a potential study patient is not on treatment their SBP must be &gt; 120 mmHg, or DBP
             &gt; 80 mmHg

          -  Whether on treatment or not SBP must be &lt;160 mmHg and DBP must be &lt; 100 mmHg (BP is
             not an outcome. Controlled BP is for participant safety)

          -  Screening Vitamin D (D2 and D3 level) &gt;5 and &lt; 25 ng/ml (recommended normal level is &gt;
             30 ng/ml)

          -  Body mass index (BMI) &gt; 25 kg/m2 and &lt; 45 kg/m2

          -  Any female of non-childbearing potential, including any female who:

               -  has had a hysterectomy,

               -  has had a bilateral oophorectomy,

               -  has had a bilateral tubal ligation or

               -  is postmenopausal (demonstration of total cessation of menses for ≥ 1 year prior
                  to the date of the screening visit)

          -  Any female of child-bearing potential must agree to use at least one form of
             contraception (may be a barrier method), during the full duration of the study.

        Exclusion Criteria:

          -  Concurrent Disease:

               -  Poorly controlled high blood pressure (SBP ≥160 mmHg or DBP ≥ 100 mmHg)

               -  Poorly controlled diabetes (HbA1c &gt;8.5%)

               -  Screening Vitamin D (D2 and D3 level) &lt; 5 or &gt; 25 ng/ml (recommended normal level
                  is &gt; 30 ng/ml)

               -  Estimated glomerular filtration rate (eGFR) &lt; 45 ml/min

               -  Evidence of disease that could result in hypercalcemia

               -  History of kidney stones (less than one year prior to screening)

               -  History of drug, alcohol, or illicit substance abuse (within the past 6 months)

               -  History of another chronic disease which the investigator feels should preclude
                  the subject from entering the study (e.g. cancer, immunologic disorder)

               -  Liver function tests (LFTs) greater than twice the upper limit of normal

               -  Subjects requiring chronic use of nonsteroidal anti-inflammatory drugs or aspirin
                  &gt;325 mg/day

               -  Subjects requiring treatment with other vitamin D preparations containing more
                  than 400 IU of vitamin D

               -  Subjects requiring chronic use of immunosuppressive therapy or corticosteroids

               -  Recent (&lt;6 months) myocardial infarction, stroke, or hospitalization for
                  congestive heart failure

               -  Subjects with clinically apparent hypothyroidism or thyrotoxicosis

               -  Allergy/intolerance: known allergy to oral vitamin D or microcrystalline
                  cellulose

               -  Any female of child-bearing potential who declines to use some method of birth
                  control during the study period

        Other:

          -  Concurrent participation in other clinical trials or taking experimental medications
             or within 30 days of completing another trial or study.

          -  Patients who are unable to give informed consent

          -  Patients who, in the opinion of the Investigator, have a condition which would
             interfere with their evaluation (e.g. severe mental health disorder)

          -  Patients who, in the opinion of the Investigator, may experience an unacceptable
             health risk by participating in this study

          -  Patients who are pregnant or lactating

          -  Not African- American or Black by self-identification

          -  Body mass index (BMI) &gt; 45 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Martins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University of Medicine and Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Drew University</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <results_first_submitted>March 22, 2018</results_first_submitted>
  <results_first_submitted_qc>April 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2018</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles Drew University of Medicine and Science</investigator_affiliation>
    <investigator_full_name>David Martins</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Hypovitaminosis D</keyword>
  <keyword>HTN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
        </group>
        <group group_id="P2">
          <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
          <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
        </group>
        <group group_id="B2">
          <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
          <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="219"/>
            <count group_id="B3" value="330"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="9.7"/>
                    <measurement group_id="B2" value="51.3" spread="9.7"/>
                    <measurement group_id="B3" value="52.0" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma PTH Level</title>
        <description>Building upon our hypothesis above, this aim exploits the fact that the nuclear Vit-D Receptor (VDR) regulates parathyroid hormone (PTH) gene transcription. Therefore the plasma PTH level serves as a sensitive biomarker of the Vit-D nutri-genomic response. This aim will define the multivariate determinants (covariates such as age, BMI, baseline Vit-D level and dietary calcium) of the Vit-D-PTH level relationship (the primary outcome variable) in African-Americans. It is anticipated that the Vit-D supplementation trial will document a wide variance of Vit-D-PTH level relationships that will identify patients at the upper and lower quartiles of the distribution that are either ‘nutrient-responsive’ or ‘nutrient-resistant’. These studies should help identify the ‘clinical’ characteristics of the sub-set of African-Americans that exhibit the poorest response to Vit-D supplementation.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PTH Level</title>
          <description>Building upon our hypothesis above, this aim exploits the fact that the nuclear Vit-D Receptor (VDR) regulates parathyroid hormone (PTH) gene transcription. Therefore the plasma PTH level serves as a sensitive biomarker of the Vit-D nutri-genomic response. This aim will define the multivariate determinants (covariates such as age, BMI, baseline Vit-D level and dietary calcium) of the Vit-D-PTH level relationship (the primary outcome variable) in African-Americans. It is anticipated that the Vit-D supplementation trial will document a wide variance of Vit-D-PTH level relationships that will identify patients at the upper and lower quartiles of the distribution that are either ‘nutrient-responsive’ or ‘nutrient-resistant’. These studies should help identify the ‘clinical’ characteristics of the sub-set of African-Americans that exhibit the poorest response to Vit-D supplementation.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.29" spread="23.82"/>
                    <measurement group_id="O2" value="60.73" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.88" spread="22.23"/>
                    <measurement group_id="O2" value="54.05" spread="26.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vitamin D3 Level</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin D3 Level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.02" spread="4.51"/>
                    <measurement group_id="O2" value="16.55" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.64" spread="4.90"/>
                    <measurement group_id="O2" value="32.73" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: Cysteine</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: Cysteine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cysteine (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.5" spread="41.5"/>
                    <measurement group_id="O2" value="252.4" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cysteine (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.0" spread="38.7"/>
                    <measurement group_id="O2" value="241.2" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: Homocysteine</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: Homocysteine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Homocysteine (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="3.3"/>
                    <measurement group_id="O2" value="11.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homocysteine (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="3.0"/>
                    <measurement group_id="O2" value="11.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: GSH</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: GSH</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSH (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.2"/>
                    <measurement group_id="O2" value="4.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSH (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.9"/>
                    <measurement group_id="O2" value="3.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: Isoprostane</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: Isoprostane</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Isoprostane (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8298.6" spread="8504.8"/>
                    <measurement group_id="O2" value="11914.9" spread="17904.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Isoprostane (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687.1" spread="54460.2"/>
                    <measurement group_id="O2" value="9979.7" spread="8630.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout duration of study = 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
Placebo</description>
        </group>
        <group group_id="E2">
          <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
          <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractured Right Arm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Neck Strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Right Leg Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Back Pain Exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Left Shoulder Muscle Strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Neck Muscle Cramp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Value</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Injury - Right Lower Extremity (Pre-Existing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rash on Bilateral Lower Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Martins</name_or_title>
      <organization>Charles Drew University of Medicine and Science</organization>
      <phone>323-568-3353</phone>
      <email>davidmartins@cdrewu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

